Drug Profile


Alternative Names: 2126458; GSK-212; GSK-2126458; GSK-458

Latest Information Update: 25 Aug 2016

Price : *
* Final gross price and currency may vary according to local VAT and billing address.

At a glance

  • Originator GlaxoSmithKline
  • Class Antineoplastics; Benzene derivatives; Fluorobenzenes; Pyridazines; Pyridines; Quinolines; Small molecules; Sulfonamides
  • Mechanism of Action 1 Phosphatidylinositol 3 kinase inhibitors; MTOR protein inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • New Molecular Entity Yes

Highest Development Phases

  • Phase I Idiopathic pulmonary fibrosis; Lymphoma; Solid tumours

Most Recent Events

  • 01 Jul 2016 GlaxoSmithKline completes a phase I trial in Idiopathic pulmonary fibrosis in United Kingdom (NCT01725139)
  • 01 Apr 2015 GlaxoSmithKline suspends phase I trial in Idiopathic pulmonary fibrosis in United Kingdom (NCT01725139)
  • 16 Oct 2013 GSK 2126458 is still in phase I trials as monotherapy for Lymphoma and Solid tumours in the USA and Netherlands and Idiopathic pulmonary fibrosis in United Kingdom
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at so we can help.

Back to top